India  

Novavax COVID-19 vaccine

Vaccine candidate against COVID-19

Novavax COVID-19 vaccine    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Novavax COVID-19 vaccine: Vaccine candidate against COVID-19
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Full results from Nuvaxovid's pivotal phase III trial were published in December 2021.

0
shares
ShareTweetSavePostSend
 

You Might Like


SII gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

The government has allowed Serum Institute of India (SII) to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported..
IndiaTimes - Published

Covid-19 vaccine: SII's Covovax gets nod for emergency use in children aged 7 to 11 years

The DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and in 12-17 years age group on March 9, 2022.
DNA - Published Also reported by •IndiaTimes

Covovax vaccine: Government panel recommends emergency approval for use in 7-11 year olds

The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase.
DNA - Published Also reported by •IndiaTimes

Covid-19 vaccine: SII significantly lowers price of each dose of Covovax

This comes a day after Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres.
DNA - Published

SII lowers each dose of Covovax jab from Rs 900 to Rs 225 excluding taxes


IndiaTimes - Published

Covid-19 vaccine Covovax now available for children in India: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children. He also hailed PM Narendra Modi for his vision of providing..
IndiaTimes - Published

Govt unlikely to procure SII’s Covovax for 12-17 age group

As majority of youngsters has already taken the first dose of Covid vaccine, the government is unlikely to procure Serum Institute of India’s Covovax for use in adolescents of 12-17 years under the..
IndiaTimes - Published

SII gets NTAGI nod for use of Covovax in 12-17 age group


IndiaTimes - Published

NTAGI panel recommends inclusion of Covovax in inoculation drive for 12-17 age group

Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, r
DNA - Published Also reported by •IndiaTimes

SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group

Covovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.
DNA - Published

SII’s Covovax for those aged 12+ gets panel nod

The Covid-19 working group under the government’s vaccine advisory body has recommended use of the Serum Institute of India’s Covovax in the national vaccination programme for those aged 12 years..
IndiaTimes - Published

SII's Covovax recommended by government panel for inclusion in national Covid-19 vaccination drive

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group.
DNA - Published

NTAGI's Covid working group to review SII's Covovax data for use in 12 year olds and above


IndiaTimes - Published

Novavax says its Covid vaccine gets India authorisation for adolescents

Novavax Inc on Tuesday said that the Drugs Controller General of India (DCGI) has granted emergency use authorisation for its Covid-19 vaccine for adolescents aged 12 to 17 in the country. The..
IndiaTimes - Published

Covid-19: Covovax gets DCGI’s EUA nod for 12-17-year-olds

In a move that will further expand the basket of Covid vaccines approved for adolescents, the drug regulator has given emergency approval to Serum Institute of India’s Covovax for use in 12-17 year..
IndiaTimes - Published

DCGI's EUA nod to Covovax for 12-17 years age group

India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official..
IndiaTimes - Published

SII's Covovax granted emergency use approval for adults, children above 12

The government has still not not taken a decision on vaccinating those aged below 15 years.
DNA - Published

Covid-19: SII's Covovax vaccine recommended for Phase 3 trial as booster dose in adults

The Pune-based SII had sought the permission from the DCGI to conduct Phase 3 study to evaluate the safety and immunogenicity of Covovax.
DNA - Published Also reported by •IndiaTimes

Government panel recommends EUA for Covid vaccine Covovax for 12-17 age group

Prakash Kumar Singh, director-government and regulatory affairs at Serum Institute of India (SII), had submitted an application to the DCGI on February 21, seeking EUA for Covovax for the 12 to 17..
IndiaTimes - Published

SII seeks permission for phase-3 study of Covid vaccine Covovax as booster dose in adults


IndiaTimes - Published Also reported by •DNA

230 kids aged 2-6 become youngest to get Covid jabs in Covovax trial

A group of 230 children aged two to six have become the youngest in the country to get a Covid vaccine after they were given at least one dose during trials of the Covovax jab, manufacturer Serum..
IndiaTimes - Published

India approves Corbevax, Covovax vaccines for emergency use


IndiaTimes - Published

Covovax approval to strengthen immunization efforts in India, lower & middle income countries: SII


IndiaTimes - Published

Bio E's Corbevax, SII's Covovax & antiviral drug Molnupiravir get EUA nod

In a significant boost for India’s fight against Covid-19, the Central Drugs Standard Control Organisation (CDSCO) has granted emergency use authorisation for two more Covid-19 vaccines – Corbevax..
IndiaTimes - Published

Covid-19: Govt approves emergency use of Corbevax and Covovax vaccines and anti-viral pill Molnupiravir

The government on Tuesday announced that it has approved emergency use of two more Covid-19 vaccines - Corbevax and Covovax - and Molnupiravir, an anti-viral pill. With the nod from the government for..
IndiaTimes - Published

BREAKING: Corbevax, Covovax, anti-viral drug Molnupiravir approved for emergency use in India

The vaccines that have so far received emergency use authorisation have increased to 8, as of now.
DNA - Published

Govt panel recommends EUA for Covid-19 vaccines Covovax, Corbevax, anti-Covid pill molnupiravir


IndiaTimes - Published

CDSCO panel recommends emergency use authorisation for SII's Covid vaccine Covovax


IndiaTimes - Published

Yechury questions Modi govt intent on not allowing Covovax


IndiaTimes - Published

DCGI seeks more data from SII over its application seeking emergency authorisation for Covovax


IndiaTimes - Published

Serum Institute CEO hails WHO's approval of Covovax for emergency use


IndiaTimes - Published

WHO approves SII's Covovax for emergency use

Covavax is the Indian version of the Novavax vaccine brought in India by the Serum Institute of India for children.
DNA - Published

Serum plans to launch Novavax shot for children in six months


IndiaTimes - Published

Novavax COVID jab manufacturer reveals £400m Teesside plant expansion

novavax covid jab manufacturer reveals £400m teesside plant expansion
The company slated to manufacture tens of millions of Novavax coronavirus vaccines at its plant on Teesside has announced a £400m expansion plan for the site.
Sky News - Published

New variant may force drug companies to tweak Covid vaccination plans

The emergence of the Omicron strain could lead drug companies scrambling to the drawing board to tweak their Covid-19 vaccine plans. US firm Novavax and Russia’s Gamaleya Institute said on Monday..
IndiaTimes - Published

Govt panel seeks additional data from SII, says Covovax not yet been approved in country of origin


IndiaTimes - Published

Novavax files for emergency use listing of Covid-19 vaccine with WHO


IndiaTimes - Published

Novavax Covid-19 vaccine receives first emergency use authorization

Novavax Inc and partner Serum Institute of India said on Monday they received emergency use authorization for their Covid-19 vaccine in Indonesia, making it the first approval anywhere in the world for..
IndiaTimes - Published

SII now aims to include kids aged 2 to 6 in vaccination trials in a month

The Serum Institute of India has expanded Covovax’s paediatric trial in seven to 11 years age bracket across 10 sites in India, including Pune, after ensuring vaccine safety in adolescents. The..
IndiaTimes - Published

Recruitment of volunteers for trial of Covid vaccine Covovax on children begins


IndiaTimes - Published

Hopeful of launching Covovax for adults in October this year, for children in Q1-2022: Serum CEO Adar Poonawalla


IndiaTimes - Published

Govt panel recommends against allowing SII to conduct trial of Covovax on children aged 2-17 yrs

An expert panel of the country's central drug authority on Wednesday recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of Covid-19 vaccine..
IndiaTimes - Published

Serum Institute's COVID-19 vaccine 'Covovax' likely to launch by September

The new vaccine shall be launched under the brand name of Covovax, which SII is manufacturing in partnership with US pharmaceutical firm Novovax.
DNA - Published

COVID-19: Serum Institute's Novavax vaccine shows 90% overall efficacy

Novavax in collaboration with Indian drug manufacturer Serum Institute of India is manufacturing these vaccines for India and low-income countries.
DNA - Published

Covid-19: Novavax set for India launch with Serum Institute of India as manufacturing partner

The uncertain path to authorisation in the US for Novavax despite passing the efficacy test with an impressive score of 90.4% might see India emerge as a major destination for the shots with the Serum..
IndiaTimes - Published

Novavax COVID jab 100% effective in protecting against moderate and severe disease, trial suggests

Novavax has said its COVID-19 vaccine is 100% effective in protecting against "moderate and severe disease" following its phase three trial results.
Sky News - Published

Mix and match vaccine study extended to include Moderna and Novavax jabs

mix and match vaccine study extended to include moderna and novavax jabs
A study assessing the benefits of mixing and matching coronavirus vaccines has been extended to include the Moderna and Novavax jabs.
Sky News - Published


 Page 1  〉